Ari

BNS Ophthalmics appoints Joseph Papa and Ari Kellen to the Board of Directors

Retrieved on: 
Wednesday, June 21, 2023

ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.

Key Points: 
  • ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.
  • Joseph and Ari, having worked together, bring an impressive and successful track record of leadership and achievements.
  • The presence of Joseph and Ari in the BNSO Board reflects their confidence in BNSO scientific potential and excitement about the future prospects of BNSO.
  • Aris Mitsopoulos, Vice President of RAFARM and CEO of BNSO, stated: "We are thrilled to welcome Joseph Papa and Ari Kellen, to our esteemed Board of Directors.

Dr. Ari Sareli to Lead Clinical Efforts for Memorial Healthcare System as Chief Medical Officer

Retrieved on: 
Thursday, March 23, 2023

HOLLYWOOD, Fla., March 23, 2023 /PRNewswire-PRWeb/ -- Dr. Aharon (Ari) Sareli, a critical care physician and longtime clinical and executive leader, has been named chief medical officer by Memorial Healthcare System. In a related move, Memorial appointed Dr. Holly Neville its associate chief medical officer.

Key Points: 
  • Sareli, along with Dr. Holly Neville in an associate CMO role, bring current, front-line experience to executive leadership positions
    HOLLYWOOD, Fla., March 23, 2023 /PRNewswire-PRWeb/ -- Dr. Aharon (Ari) Sareli, a critical care physician and longtime clinical and executive leader, has been named chief medical officer by Memorial Healthcare System .
  • In a related move, Memorial appointed Dr. Holly Neville its associate chief medical officer.
  • "Both Ari and Holly have worked throughout our system, earning respect and elevating patient care through collaborations with fellow physicians, nurses, and operational teams," said K. Scott Wester, Memorial Healthcare System CEO.
  • He was appointed director of Memorial Hospital West's Critical Care in 2010 and chief of critical care for the system in 2012.

Orion and Bayer expand clinical development program for darolutamide in prostate cancer

Retrieved on: 
Thursday, March 23, 2023

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline

Key Points: 
  • Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline
    Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage
    Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer.
  • Darolutamide is already approved under the brand name Nubeqa® for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well as metastatic hormone-sensitive prostate cancer (mHSPC).
  • “Darolutamide has already shown its beneficial treatment effects in two patient groups: patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease as well as in patients with metastatic hormone-sensitive prostate cancer in combination with chemotherapy.
  • The compound is also being investigated in further studies across various stages of prostate cancer, including in the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for metastatic hormone-sensitive prostate cancer (mHSPC), as well as the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) led international Phase III co-operative group DASL-HiCaP (ANZUP1801) trial evaluating darolutamide as an adjuvant treatment for localised prostate cancer with very high risk of recurrence.

Darolutamide approved for additional prostate cancer indication in China

Retrieved on: 
Monday, March 20, 2023

The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Key Points: 
  • The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
  • Darolutamide is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.
  • Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms.
  • This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC.

Darolutamide receives EU approval for additional indication in prostate cancer

Retrieved on: 
Wednesday, March 1, 2023

The European Commission has granted marketing authorisation in the European Union (EU) for darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Key Points: 
  • The European Commission has granted marketing authorisation in the European Union (EU) for darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
  • Darolutamide is already approved under the brand name Nubeqa® for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.
  • Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms.
  • Darolutamide is being investigated in a broad development program with an additional three ongoing or planned large clinical studies, to investigate its potential across prostate cancer patients from the early- to the late-stage of this disease.

Darolutamide receives approval for additional prostate cancer indication in Japan

Retrieved on: 
Monday, February 27, 2023

The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer.

Key Points: 
  • The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer.
  • Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms.
  • Darolutamide is being investigated in a broad development program with three additional ongoing or planned large clinical studies, to evauate its potential across prostate cancer patients from the early- to the late-stage of this disease.
  • This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC.

Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer

Retrieved on: 
Friday, January 27, 2023

Darolutamide is already approved under the brand name Nubeqa® for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.

Key Points: 
  • Darolutamide is already approved under the brand name Nubeqa® for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.
  • The final decision from the European Commission on the marketing authorisation is expected in the coming months.
  • This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC.
  • Bayer is responsible for global commercialisation, with co-promotion from Bayer and Orion in certain European markets, e.g.

Fluent Launches Purpose to Empower Consumer Financial Decisions

Retrieved on: 
Wednesday, October 5, 2022

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, announced the launch of Purpose, a mobile app focused on enabling consumer financial decisions and wellness through content and brand discovery.

Key Points: 
  • NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, announced the launch of Purpose, a mobile app focused on enabling consumer financial decisions and wellness through content and brand discovery.
  • Ari Kassman, an entrepreneur with deep experience building technology companies, will join Fluent to help grow Purpose and develop other community-driven products.
  • Creating quality, relevant experiences sits at the core of Fluents consumer-centric strategy, said Ryan Schulke, Chief Strategy Officer and Co-Founder of Fluent.
  • With the launch of Purpose, we empower people to improve their financial wellness and grow their savings during a turbulent economic time.

Bridgeline Wins Over $1 Million in SaaS License Sales in its Fourth Quarter of Fiscal 2022

Retrieved on: 
Tuesday, October 4, 2022

Bridgeline reported 28 SaaS license sales totaling over $1 Million in total contract value with $340 Thousand in annual recurring revenue for its fourth quarter of fiscal year 2022.

Key Points: 
  • Bridgeline reported 28 SaaS license sales totaling over $1 Million in total contract value with $340 Thousand in annual recurring revenue for its fourth quarter of fiscal year 2022.
  • Existing Bridgeline customers including HP, 7-Eleven, and SAGE Publishing expanded their commitment to Bridgeline this quarter with further investments in Bridgeline software and services.
  • In 2022, Bridgeline acquired customers in new industries and expanded customer licenses through cross-selling, said Ari Kahn, Bridgelines President and Chief Executive Officer.
  • This incremental license ARR has helped us deliver double-digit growth in Fiscal Year 2022.

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

Retrieved on: 
Tuesday, August 30, 2022

Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.

Key Points: 
  • Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.
  • Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.